Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 753-758

  Jiang, Lei ^a   Yu, Kang ^a,b   Du, Jimei ^b   Ni, Wuhua ^a   Han, Yixiang ^a   Gao, Shenmeng ^a   Li, Haiying ^a   Wu, Jianbo ^a   Zheng, Yihu ^a   Tan, Yingxia ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

References

Indexed keywords

CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMID DNA; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; RAJI CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; WESTERN BLOTTING;

EID: 79958072416     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.308     Document Type: Article

References (24)

1. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H and Bonavida B: Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 24: 8114-8127, 2005.
2. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C and Bonavida B: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 23: 3530-3540, 2004.
3. Till BG and Press OW: Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther 9: 1407-1425, 2009.
4. Jensen MC, Cooper LJ, Wu AM, Forman SJ and Raubitschek A: Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 5: 131-138, 2003.
5. Eshhar Z, Waks T, Gross G and Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA 90: 720-724, 1993.
6. Hombach A, Wieczarkowiecz A, Marquardt T, et al: Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167: 6123-6131, 2001.
7. Yu K, Hu Y, Tan Y, et al: Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma 49: 1368-1373, 2008.
8. Zheng Y, Yu K, Du J, et al: Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene transfected T cells. J Exp Clin Cancer Res 29: 121, 2010.
9. Jiang L, Chen Y, Chan CY, et al: Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett 274: 101-108, 2009.
10. Wang H, Wei H, Zhang R, et al: Genetically targeted T cells eradicate established breast cancer in syngeneic mice. Clin Cancer Res 15: 943-950, 2009.
11. Teng MW, Kershaw MH, Moeller M, Smyth MJ and Darcy PK: Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther 15: 699-708, 2004.
12. Haynes NM, Trapani JA, Teng MW, et al: Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163, 2002.
13. Rossig C and Brenner MK: Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 10: 5-18, 2004.
14. Finney HM, Akbar AN and Lawson AD: Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172: 104-113, 2004.
15. El-Far M, Fouda M, Yahya R and el-Baz H: Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem 60: 253-258, 2004.
16. Voorzanger N, Touitou R, Garcia E, et al: Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56: 5499-5505, 1996.
17. Benjamin D, Park CD and Sharma V: Human B cell interleukin 10. Leuk Lymphoma 12: 205-210, 1994.
18. Alas S, Emmanouilides C and Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7: 709-723, 2001.
19. Vockerodt M, Haier B, Buttgereit P, Tesch H and Kube D: The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 280: 183-198, 2001.
20. Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood 101: 4667-4679, 2003.
21. Pedersen IM, Buhl AM, Klausen P, Geisler CH and Jurlander J: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99: 1314-1319, 2002.
22. Jazirehi AR, Gan XH, De Vos S, Emmanouilides C and Bonavida B: Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2: 1183-1193, 2003.
23. Alas S and Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137-5144, 2001.
24. Ma W, Lim W, Gee K, et al: The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 276: 13664-13674, 2001.